ANI Pharmaceuticals (ANIP) and Nabriva Therapeutics AG (NBRV) Financial Contrast

ANI Pharmaceuticals (NASDAQ: ANIP) and Nabriva Therapeutics AG (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership.

Volatility & Risk

ANI Pharmaceuticals has a beta of 3.1, suggesting that its stock price is 210% more volatile than the S&P 500. Comparatively, Nabriva Therapeutics AG has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for ANI Pharmaceuticals and Nabriva Therapeutics AG, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ANI Pharmaceuticals 0 1 2 0 2.67
Nabriva Therapeutics AG 0 0 7 0 3.00

ANI Pharmaceuticals presently has a consensus target price of $65.33, suggesting a potential upside of 30.43%. Nabriva Therapeutics AG has a consensus target price of $16.86, suggesting a potential upside of 145.73%. Given Nabriva Therapeutics AG’s stronger consensus rating and higher probable upside, analysts clearly believe Nabriva Therapeutics AG is more favorable than ANI Pharmaceuticals.

Valuation & Earnings

This table compares ANI Pharmaceuticals and Nabriva Therapeutics AG’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
ANI Pharmaceuticals $158.12 million 3.69 $59.01 million $0.46 108.89
Nabriva Therapeutics AG $6.01 million 30.63 -$59.30 million ($2.45) -2.80

ANI Pharmaceuticals has higher revenue and earnings than Nabriva Therapeutics AG. Nabriva Therapeutics AG is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

55.9% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 68.6% of Nabriva Therapeutics AG shares are owned by institutional investors. 31.8% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 2.8% of Nabriva Therapeutics AG shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares ANI Pharmaceuticals and Nabriva Therapeutics AG’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ANI Pharmaceuticals 3.35% 22.70% 11.48%
Nabriva Therapeutics AG N/A -90.54% -72.82%

Summary

ANI Pharmaceuticals beats Nabriva Therapeutics AG on 8 of the 13 factors compared between the two stocks.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.

Nabriva Therapeutics AG Company Profile

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin. Lefamulin is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. Lefamulin is being evaluated in two global, registrational Phase III clinical trials in patients with moderate to severe community-acquired bacterial pneumonia (CABP).It seeks to further pursue development of lefamulin for additional indications, including the treatment of acute bacterial skin and skin structure infections (ABSSSI), and is developing a formulation of lefamulin appropriate for pediatric use.

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply